Stemgenics
Stemgenics develops technology to convert mature skin cells into personalized stem cells for tissue regeneration.
Founded
2008Stemgenics develops technology to convert mature skin cells into personalized stem cells for tissue regeneration.
Stemgenics, founded with a mission to revolutionize regenerative medicine, focuses on developing technology that converts mature skin cells into personalized stem cells. These stem cells can potentially regenerate any tissue in the human body, offering groundbreaking solutions for various medical conditions. The company leverages a proprietary platform involving non-integrating multi-functionalized activated nanoparticles (NIMFA-NP) to deliver bioactive molecules into cells, tissues, and organs, aiming to advance therapeutic drug development.
Notable figures associated with Stemgenics include leading scientists and innovators in the field of nanotherapeutics and regenerative medicine. The company has secured investments from prominent venture capital firms specializing in biotech innovations. Key achievements include the successful development and patenting of their NIMFA-NP technology, which has broad applications in therapeutic drug development. Stemgenics' impact lies in its potential to transform personalized medicine and tissue regeneration, offering hope for treatments of previously incurable conditions.
Companies similar to Stemgenics include Personalized Stem Cells, APstem Therapeutics, MitoStem and StemBioSys.
Stemgenics was founded in 2008.
Stemgenics' headquarters is located in Seattle, WA, US.
Stemgenics' most recent funding round was for $445k (USD) in June 2018.
As of Jun 20, 2018, Stemgenics has disclosed funding of $3.5M (USD). Undisclosed round amounts are excluded.
Stemgenics has 3 employees as of Feb 5, 2024.
StemBioSys
stembiosys.com
